Treatment and prognosis of primary ocular adnexal extranodal marginal zone mucosa-associated lymphoid tissue lymphoma: a report from a single center.
10.3760/cma.j.issn.0253-2727.2022.03.005
- Author:
Xin LI
1
;
Jin YE
1
;
Lei YANG
1
;
Li Qiang WEI
1
;
Jia CONG
1
;
Na YAO
1
;
Jing YANG
1
;
Jing Wen WANG
1
Author Information
1. Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Lymphoma, B-cell, marginal zone;
Prognosis;
Radiotherapy
- MeSH:
Eye Neoplasms/radiotherapy*;
Humans;
Lymphoid Tissue/pathology*;
Lymphoma, B-Cell, Marginal Zone/therapy*;
Prognosis;
Retrospective Studies;
Treatment Outcome
- From:
Chinese Journal of Hematology
2022;43(3):209-214
- CountryChina
- Language:Chinese
-
Abstract:
Objective: This study aimed to see how different initial treatment regimens affected the long-term prognosis of patients with extranodal marginal zone mucosa-associated lymphoid tissue lymphoma confining to the ocular adnexal (OAML) . Methods: Between April 2008 and April 2019, 109 patients with initial mucosa-associated lymphoid tissue confining to ocular adnexal were evaluated and followed-up, and the prognosis of various initial treatment regimens were examined. Results: A total of 36 patients underwent complete surgical resection of the lesions, and 73 patients had residual lesions after surgery, of which 37 patients chose watchful waiting, and 36 patients chose treatment. The treatment regimen included local radiotherapy and systemic treatment (chemotherapy, immunochemotherapy, the combination of radiotherapy and chemotherapy, etc.) , and no serious toxic and side effects were observed in patients receiving systemic treatment. The median follow-up time was 61 (10-142) months. The 5-year and 10-year progression-free survival (PFS) of monocular involvement patients were 78.2% and 76.0% . The 5-year and 10-year PFS rates of patients with binocular involvement were 64.4% and 23.5%. There was significant diference in PFS between patients with monocular and binocular involvement (P=0.010) . Patients who received additional treatment had higher PFS than those patients in the watchful waiting group (P=0.046) . The 5-year PFS was 71.4% and 90.1% among patients in the watchful waiting group and those who received additional treatment, whereas the 10-year PFS was 63.5% and 75.1% , respectively. Patients with OAML were still a risk of disease progression after 5 years. Conclusions: Patients with binocular involvement OAML at the start of the disease had a poor prognosis, but treatment could reduce the risk of recurrence/progression. Systemic therapy is one of the first-line treatment options for patients with OAML, who require long-term monitoring.
